368 related articles for article (PubMed ID: 17979837)
1. Ecto-calreticulin in immunogenic chemotherapy.
Obeid M; Tesniere A; Panaretakis T; Tufi R; Joza N; van Endert P; Ghiringhelli F; Apetoh L; Chaput N; Flament C; Ullrich E; de Botton S; Zitvogel L; Kroemer G
Immunol Rev; 2007 Dec; 220():22-34. PubMed ID: 17979837
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic cancer cell death: a key-lock paradigm.
Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
[TBL] [Abstract][Full Text] [Related]
3. Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin.
Tufi R; Panaretakis T; Bianchi K; Criollo A; Fazi B; Di Sano F; Tesniere A; Kepp O; Paterlini-Brechot P; Zitvogel L; Piacentini M; Szabadkai G; Kroemer G
Cell Death Differ; 2008 Feb; 15(2):274-82. PubMed ID: 18034188
[TBL] [Abstract][Full Text] [Related]
4. The immunogenicity of tumor cell death.
Kepp O; Tesniere A; Zitvogel L; Kroemer G
Curr Opin Oncol; 2009 Jan; 21(1):71-6. PubMed ID: 19125021
[TBL] [Abstract][Full Text] [Related]
5. Immunogenic cell death modalities and their impact on cancer treatment.
Kepp O; Tesniere A; Schlemmer F; Michaud M; Senovilla L; Zitvogel L; Kroemer G
Apoptosis; 2009 Apr; 14(4):364-75. PubMed ID: 19145485
[TBL] [Abstract][Full Text] [Related]
6. Molecular characteristics of immunogenic cancer cell death.
Tesniere A; Panaretakis T; Kepp O; Apetoh L; Ghiringhelli F; Zitvogel L; Kroemer G
Cell Death Differ; 2008 Jan; 15(1):3-12. PubMed ID: 18007663
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic death of colon cancer cells treated with oxaliplatin.
Tesniere A; Schlemmer F; Boige V; Kepp O; Martins I; Ghiringhelli F; Aymeric L; Michaud M; Apetoh L; Barault L; Mendiboure J; Pignon JP; Jooste V; van Endert P; Ducreux M; Zitvogel L; Piard F; Kroemer G
Oncogene; 2010 Jan; 29(4):482-91. PubMed ID: 19881547
[TBL] [Abstract][Full Text] [Related]
8. Witch hunt against tumor cells enhanced by dendritic cells.
Locher C; Rusakiewicz S; Tesnière A; Ghiringhelli F; Apetoh L; Kroemer G; Zitvogel L
Ann N Y Acad Sci; 2009 Sep; 1174():51-60. PubMed ID: 19769736
[TBL] [Abstract][Full Text] [Related]
9. Human tumor cells killed by anthracyclines induce a tumor-specific immune response.
Fucikova J; Kralikova P; Fialova A; Brtnicky T; Rob L; Bartunkova J; Spísek R
Cancer Res; 2011 Jul; 71(14):4821-33. PubMed ID: 21602432
[TBL] [Abstract][Full Text] [Related]
10. Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells.
Apetoh L; Obeid M; Tesniere A; Ghiringhelli F; Fimia GM; Piacentini M; Kroemer G; Zitvogel L
Cancer Genomics Proteomics; 2007; 4(2):65-70. PubMed ID: 17804868
[TBL] [Abstract][Full Text] [Related]
11. Surface-exposed calreticulin in the interaction between dying cells and phagocytes.
Martins I; Kepp O; Galluzzi L; Senovilla L; Schlemmer F; Adjemian S; Menger L; Michaud M; Zitvogel L; Kroemer G
Ann N Y Acad Sci; 2010 Oct; 1209():77-82. PubMed ID: 20958319
[TBL] [Abstract][Full Text] [Related]
12. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia.
Wemeau M; Kepp O; Tesnière A; Panaretakis T; Flament C; De Botton S; Zitvogel L; Kroemer G; Chaput N
Cell Death Dis; 2010 Dec; 1(12):e104. PubMed ID: 21368877
[TBL] [Abstract][Full Text] [Related]
13. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.
Zappasodi R; Pupa SM; Ghedini GC; Bongarzone I; Magni M; Cabras AD; Colombo MP; Carlo-Stella C; Gianni AM; Di Nicola M
Cancer Res; 2010 Nov; 70(22):9062-72. PubMed ID: 20884630
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro.
Sonnemann J; Gressmann S; Becker S; Wittig S; Schmudde M; Beck JF
Cancer Chemother Pharmacol; 2010 Aug; 66(3):611-6. PubMed ID: 20221600
[TBL] [Abstract][Full Text] [Related]
15. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.
Chaput N; De Botton S; Obeid M; Apetoh L; Ghiringhelli F; Panaretakis T; Flament C; Zitvogel L; Kroemer G
J Mol Med (Berl); 2007 Oct; 85(10):1069-76. PubMed ID: 17891368
[TBL] [Abstract][Full Text] [Related]
16. Biphasic Increases of Cell Surface Calreticulin Following Treatment with Mitoxantrone.
Azuma Y; Suzuki K; Higai K; Matsumoto K; Tada S
Biol Pharm Bull; 2020 Oct; 43(10):1595-1599. PubMed ID: 32727970
[TBL] [Abstract][Full Text] [Related]
17. Calreticulin exposure increases cancer immunogenicity.
Clarke C; Smyth MJ
Nat Biotechnol; 2007 Feb; 25(2):192-3. PubMed ID: 17287754
[No Abstract] [Full Text] [Related]
18. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway.
Zitvogel L; Kepp O; Senovilla L; Menger L; Chaput N; Kroemer G
Clin Cancer Res; 2010 Jun; 16(12):3100-4. PubMed ID: 20421432
[TBL] [Abstract][Full Text] [Related]
19. Calreticulin exposure dictates the immunogenicity of cancer cell death.
Obeid M; Tesniere A; Ghiringhelli F; Fimia GM; Apetoh L; Perfettini JL; Castedo M; Mignot G; Panaretakis T; Casares N; Métivier D; Larochette N; van Endert P; Ciccosanti F; Piacentini M; Zitvogel L; Kroemer G
Nat Med; 2007 Jan; 13(1):54-61. PubMed ID: 17187072
[TBL] [Abstract][Full Text] [Related]
20. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination.
Kim SG; Park MY; Kim CH; Sohn HJ; Kim HS; Park JS; Kim HJ; Oh ST; Kim TG
Vaccine; 2008 Nov; 26(50):6433-40. PubMed ID: 18812201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
